                         SEQUENCE LISTING

<110>  Immatics US, Inc.
       Immatics Biotechnologies GmbH
       
<120>  METHODS FOR PEPTIDE MASS SPECTROMETRY FRAGMENTATION PREDICTION

<130>  3000011-014977

<150>  US 62/884,893
<151>  2019-08-09

<150>  DE 10 2019 121 600.1
<151>  2019-08-09

<160>  18    

<170>  PatentIn version 3.5

<210>  1
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HLA peptide

<400>  1

Ala Pro Asn Asp Phe Asn Leu Lys 
1               5               


<210>  2
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HLA peptide

<400>  2

Tyr Leu Leu Pro Ala Ile Val His Ile 
1               5                   


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Target sequence

<400>  3

Ile Ser Leu Leu Asp Ala Gln Ser Arg 
1               5                   


<210>  4
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Target sequence

<400>  4

Val Val Glu Glu Leu Cys Pro Thr Pro Glu 
1               5                   10  


<210>  5
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Target sequence

<400>  5

Leu Leu Leu Gln Trp Cys Trp Glu 
1               5               


<210>  6
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Target sequence

<400>  6

Cys Asp Val Val Ser Asn Thr Ile 
1               5               


<210>  7
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Decoy sequence

<400>  7

Arg Ser Gln Ala Asp Leu Leu Ser Ile 
1               5                   


<210>  8
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Decoy sequence

<400>  8

Glu Pro Thr Pro Cys Leu Glu Glu Val Val 
1               5                   10  


<210>  9
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Decoy sequence

<400>  9

Glu Trp Cys Trp Gln Leu Leu Leu 
1               5               


<210>  10
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Decoy sequence

<400>  10

Ile Thr Asn Ser Val Val Asp Cys 
1               5               


<210>  11
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide match

<400>  11

Val Ser Val Val Asp Leu Thr Asn Thr 
1               5                   


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide match

<400>  12

Val Val Glu Glu Leu Cys Glu Gly Met 
1               5                   


<210>  13
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide match

<400>  13

Asp Leu Leu Leu Gln Trp Cys Trp Glu Asn 
1               5                   10  


<210>  14
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide match

<400>  14

Glu Cys Asp Val Val Thr Ile Ile Ala Glu 
1               5                   10  


<210>  15
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide match

<400>  15

Gly Asp Ala Val Ile Asp Ala Leu Asn 
1               5                   


<210>  16
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide match

<400>  16

Ser Tyr Leu Phe Cys Met Glu Ala Glu 
1               5


<210>  17
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HLA peptide

<400>  17

Lys Leu Leu Glu Val Gln Ile Leu Glu 
1               5                   


<210>  18
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HLA peptide

<400>  18

Gln Leu Leu Glu Lys Val Ile Glu Leu 
1               5                   


